CU20120153A7 - Antígenos vacunales quiméricos contra el virus de la hepatitis c - Google Patents

Antígenos vacunales quiméricos contra el virus de la hepatitis c

Info

Publication number
CU20120153A7
CU20120153A7 CUP2012000153A CU20120153A CU20120153A7 CU 20120153 A7 CU20120153 A7 CU 20120153A7 CU P2012000153 A CUP2012000153 A CU P2012000153A CU 20120153 A CU20120153 A CU 20120153A CU 20120153 A7 CU20120153 A7 CU 20120153A7
Authority
CU
Cuba
Prior art keywords
virus
antigens
chimeric
chemical
against hepatitis
Prior art date
Application number
CUP2012000153A
Other languages
English (en)
Other versions
CU24112B1 (es
Inventor
Carrera Santiago Dueñas
Noriega Daylen Aguilar
Cañizares Yalena Amador
Ponce De León Liz Álvarez-Lajonchere
Donato Gillian Martínez
Blanco Sonia González
Original Assignee
Ct De Ingeniería Genética Y Biotecnología
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Ingeniería Genética Y Biotecnología filed Critical Ct De Ingeniería Genética Y Biotecnología
Priority to CU20120153A priority Critical patent/CU24112B1/es
Priority to AU2013339846A priority patent/AU2013339846B2/en
Priority to RU2015121429A priority patent/RU2639504C2/ru
Priority to CN201380064380.9A priority patent/CN104837498B/zh
Priority to PCT/CU2013/000006 priority patent/WO2014067498A1/es
Priority to CA2901346A priority patent/CA2901346C/en
Priority to IN3925DEN2015 priority patent/IN2015DN03925A/en
Priority to US14/440,443 priority patent/US9676825B2/en
Priority to ES13801461.8T priority patent/ES2644801T3/es
Priority to KR1020157012656A priority patent/KR102093495B1/ko
Priority to EP13801461.8A priority patent/EP2915544B1/en
Priority to MX2015005651A priority patent/MX358507B/es
Priority to JP2015540044A priority patent/JP6259831B2/ja
Priority to ARP130104019A priority patent/AR093341A1/es
Publication of CU20120153A7 publication Critical patent/CU20120153A7/es
Priority to ZA2015/03036A priority patent/ZA201503036B/en
Publication of CU24112B1 publication Critical patent/CU24112B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención describe antígenos vacunales quiméricos contra el virus de la hepatitis C (VHC) que comprenden regiones seleccionadas de diferentes antígenos de dicho virus, las que se ubican en un orden determinado dentro del polipéptido. Dichos antígenos quiméricos, además, pueden incluir epitopos específicos para linfocitos T auxiliadores, diseñados de forma artificial. Los antígenos quiméricos, así como las composiciones vacunales resultantes, son aplicables a la esfera de la medicina y la industria farmacéutica, y tienen un uso profiláctico y/o terapéutico contra el VHC. Las composiciones vacunales de la invención generan una respuesta inmune potente y de amplio espectro contra diferentes antígenos de dicho virus, con un mínimo de componentes.
CU20120153A 2012-11-05 2012-11-05 Antígenos vacunales quiméricos contra el virus de la hepatitis c CU24112B1 (es)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CU20120153A CU24112B1 (es) 2012-11-05 2012-11-05 Antígenos vacunales quiméricos contra el virus de la hepatitis c
US14/440,443 US9676825B2 (en) 2012-11-05 2013-10-28 Chimeric vaccine antigens against hepatitis C virus
ES13801461.8T ES2644801T3 (es) 2012-11-05 2013-10-28 Antígenos de vacuna quimérica contra el virus de la hepatitis c
CN201380064380.9A CN104837498B (zh) 2012-11-05 2013-10-28 针对丙型肝炎病毒的嵌合疫苗抗原
PCT/CU2013/000006 WO2014067498A1 (es) 2012-11-05 2013-10-28 Antígenos vacunales quiméricos contra el virus de la hepatitis c
CA2901346A CA2901346C (en) 2012-11-05 2013-10-28 Chimeric vaccine antigens against hepatitis c virus
IN3925DEN2015 IN2015DN03925A (es) 2012-11-05 2013-10-28
AU2013339846A AU2013339846B2 (en) 2012-11-05 2013-10-28 Chimeric vaccine antigens against hepatitis C virus
RU2015121429A RU2639504C2 (ru) 2012-11-05 2013-10-28 Химерные антигены для вакцины против вируса гепатита с
KR1020157012656A KR102093495B1 (ko) 2012-11-05 2013-10-28 C형 간염 바이러스에 대한 키메라 백신 항원
EP13801461.8A EP2915544B1 (en) 2012-11-05 2013-10-28 Chimeric vaccine antigens against hepatitis c virus
MX2015005651A MX358507B (es) 2012-11-05 2013-10-28 Antigenos vacunales quimericos contra el virus de la hepatitis c.
JP2015540044A JP6259831B2 (ja) 2012-11-05 2013-10-28 Ｃ型肝炎ウイルスに対するキメラワクチン抗原
ARP130104019A AR093341A1 (es) 2012-11-05 2013-11-04 Antigenos vacunales quimericos contra el virus de la hepatitis c
ZA2015/03036A ZA201503036B (en) 2012-11-05 2015-05-04 Chimeric vaccine antigens against hepatitis c virus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20120153A CU24112B1 (es) 2012-11-05 2012-11-05 Antígenos vacunales quiméricos contra el virus de la hepatitis c

Publications (2)

Publication Number Publication Date
CU20120153A7 true CU20120153A7 (es) 2014-06-27
CU24112B1 CU24112B1 (es) 2015-08-27

Family

ID=49724426

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20120153A CU24112B1 (es) 2012-11-05 2012-11-05 Antígenos vacunales quiméricos contra el virus de la hepatitis c

Country Status (15)

Country Link
US (1) US9676825B2 (es)
EP (1) EP2915544B1 (es)
JP (1) JP6259831B2 (es)
KR (1) KR102093495B1 (es)
CN (1) CN104837498B (es)
AR (1) AR093341A1 (es)
AU (1) AU2013339846B2 (es)
CA (1) CA2901346C (es)
CU (1) CU24112B1 (es)
ES (1) ES2644801T3 (es)
IN (1) IN2015DN03925A (es)
MX (1) MX358507B (es)
RU (1) RU2639504C2 (es)
WO (1) WO2014067498A1 (es)
ZA (1) ZA201503036B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10300131B2 (en) 2015-07-07 2019-05-28 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof
CN109963587A (zh) * 2016-09-21 2019-07-02 艾伯塔大学理事会 丙型肝炎病毒免疫原性组合物及其使用方法
EP3618859A4 (en) 2017-04-27 2021-05-05 Vanderbilt University HEPATITIS C VIRUS SEQUENCES AND METHODS OF USING THEREFORE
EP3765075A4 (en) 2018-03-16 2021-12-08 The Governors of the University of Alberta HEPATITIS C VIRUS PEPTIDE COMPOSITIONS AND METHOD OF USING THEREOF

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001037869A1 (en) * 1999-11-19 2001-05-31 Csl Limited Vaccine compositions
US6544780B1 (en) * 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
CU23496A1 (es) 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
JP5405832B2 (ja) * 2006-01-04 2014-02-05 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Ｈｃｖ特異的なｔ細胞の活性化
US7256008B2 (en) 2006-01-06 2007-08-14 Abbott Laboratories Determination of concentration of FK778 by competitive immunoassay
EP2222336A2 (en) * 2007-10-29 2010-09-01 GENimmune N.V. Methods and kits for inducing a ctl response using a prime boost regimen
JP5593220B2 (ja) * 2008-04-25 2014-09-17 東レ株式会社 Ｃ型肝炎ウイルス由来のキメラ遺伝子を含む核酸
WO2010033841A1 (en) * 2008-09-19 2010-03-25 Globeimmune, Inc. Immunotherapy for chronic hepatitis c virus infection
WO2010047830A2 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute Agents for hcv treatment

Also Published As

Publication number Publication date
CN104837498B (zh) 2018-05-18
IN2015DN03925A (es) 2015-10-02
CA2901346C (en) 2019-04-23
KR102093495B1 (ko) 2020-03-26
KR20150079694A (ko) 2015-07-08
RU2015121429A (ru) 2016-12-27
MX358507B (es) 2018-08-22
CN104837498A (zh) 2015-08-12
ZA201503036B (en) 2016-01-27
JP2015536936A (ja) 2015-12-24
AU2013339846B2 (en) 2017-08-17
EP2915544A1 (en) 2015-09-09
WO2014067498A1 (es) 2014-05-08
RU2639504C2 (ru) 2017-12-21
CA2901346A1 (en) 2014-05-08
US20150307558A1 (en) 2015-10-29
AR093341A1 (es) 2015-06-03
JP6259831B2 (ja) 2018-01-10
CU24112B1 (es) 2015-08-27
US9676825B2 (en) 2017-06-13
AU2013339846A1 (en) 2015-05-14
EP2915544B1 (en) 2017-08-09
ES2644801T3 (es) 2017-11-30
MX2015005651A (es) 2015-08-20

Similar Documents

Publication Publication Date Title
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
NI201800052A (es) Anticuerpos que neutraliza el virus respiratorio sincitial humano
CL2018000232A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
ZA201803978B (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
MX2018007288A (es) Anticuerpos neutralizantes para el virus de inmunodeficiencia humana.
EA201591164A1 (ru) Вакцины против вируса гриппа и их применение
MX391015B (es) Composiciones de nanoparticulas y usos de las mismas
MX370191B (es) Composiciones y su uso en el tratamiento de la inmunodeficiencia.
JOP20190097A1 (ar) الجلوبولينات المناعية واستخداماتها
EP3491026A4 (en) HUMAN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND PROCESSES
MX342716B (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
MX2016016533A (es) Combinaciones inmunogenas.
MX2015016627A (es) Vacuna para la malaria.
EP2897640A4 (en) HEPATITIS B VIRUS CORE PROTEIN AND SURFACE ANTIBODY PROTEIN AND VACCINE THEREWITH
ZA202403393B (en) Synthetic chimeric poxviruses
MX391149B (es) Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion.
AR102547A1 (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
AR093341A1 (es) Antigenos vacunales quimericos contra el virus de la hepatitis c
EA201792512A1 (ru) Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник
MX2019007924A (es) Vacunas contra la influenza.
IN2014DN09445A (es)
MX2016004754A (es) Nuevo peptido que tiene cuatro epitopos de linfocitos t citotoxicos (ctl) enlazados.
IL258238B (en) Hiv antibody compositions and methods of use
ECSP18039827A (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano

Legal Events

Date Code Title Description
FG Grant of patent